James P Stewart
Overview
Explore the profile of James P Stewart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
3174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Alcoceba M, Stewart J, Garcia-Alvarez M, Diaz L, Jimenez C, Medina A, et al.
Br J Haematol
. 2024 May;
205(1):109-121.
PMID: 38811363
Circulating tumour DNA (ctDNA) allows genotyping and minimal residual disease (MRD) detection in lymphomas. Using a next-generation sequencing (NGS) approach (EuroClonality-NDC), we evaluated the clinical and prognostic value of ctDNA...
12.
Fernandez J, Marin A, Rosales R, Penrice-Randal R, Mlcochova P, Alvarez Y, et al.
Biochim Biophys Acta Mol Basis Dis
. 2024 Apr;
1870(5):167193.
PMID: 38648902
SARS-CoV-2 infection can cause severe pneumonia, wherein exacerbated inflammation plays a major role. This is reminiscent of the process commonly termed cytokine storm, a condition dependent on a disproportionated production...
13.
Michael B, Dunai C, Needham E, Tharmaratnam K, Williams R, Huang Y, et al.
Nat Commun
. 2024 Apr;
15(1):2918.
PMID: 38575615
No abstract available.
14.
Sheng Y, Deng Y, Li X, Ji P, Sun X, Liu B, et al.
J Virol
. 2024 Mar;
98(4):e0164923.
PMID: 38548704
Importance: Hepatitis E virus (HEV) infection is the leading cause of acute viral hepatitis worldwide. After the synthesis and modification in the cells, the mature ORF3 protein is essential for...
15.
Penrice-Randal R, Bentley E, Sharma P, Kirby A, Donovan-Banfield I, Kipar A, et al.
bioRxiv
. 2024 Mar;
PMID: 38464327
Objectives: Immunocompromised individuals are susceptible to severe COVID-19 and potentially contribute to the emergence of variants with altered pathogenicity due to persistent infection. This study investigated the impact of immunosuppression...
16.
Deng Y, Sheng Y, Zhang G, Sun Y, Wang L, Ji P, et al.
J Virol
. 2024 Jan;
98(2):e0165023.
PMID: 38271227
Vaccination is the most effective method to protect humans and animals from diseases. Anti-idiotype vaccines are safer due to their absence of pathogens. However, the commercial production of traditional anti-idiotype...
17.
Zhuang X, Gallo G, Sharma P, Ha J, Magri A, Borrmann H, et al.
iScience
. 2024 Jan;
27(1):108763.
PMID: 38261926
Respiratory syncytial virus (RSV) is a global healthcare problem, causing respiratory illness in young children and elderly individuals. Our knowledge of the host pathways that define susceptibility to infection and...
18.
Michael B, Dunai C, Needham E, Tharmaratnam K, Williams R, Huang Y, et al.
Nat Commun
. 2023 Dec;
14(1):8487.
PMID: 38135686
To understand neurological complications of COVID-19 better both acutely and for recovery, we measured markers of brain injury, inflammatory mediators, and autoantibodies in 203 hospitalised participants; 111 with acute sera...
19.
Gallardo-Toledo E, Neary M, Sharp J, Herriott J, Kijak E, Bramwell C, et al.
Viruses
. 2023 Nov;
15(11).
PMID: 38005839
Pibrentasvir (PIB) has been demonstrated to block exonuclease activity of the SARS-CoV-2 polymerase, protecting favipiravir (FVP) and remdesivir (RDV) from post-incorporation excision and eliciting antiviral synergy in vitro. The present...
20.
Box H, Sharp J, Pennington S, Kijak E, Tatham L, Caygill C, et al.
J Antimicrob Chemother
. 2023 Nov;
79(1):172-178.
PMID: 37995258
Objectives: Antiviral interventions are required to complement vaccination programmes and reduce the global burden of COVID-19. Prior to initiation of large-scale clinical trials, robust preclinical data to support candidate plausibility...